Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Active negotiation
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Braftovi, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test
Last updated:
May 6, 2026
Status:
Negotiations were not pursued
Manufacturer:
Sun Pharma Canada Inc.
Indication:
Multiple Indications
Last updated:
May 6, 2026
Status:
Active negotiation
Manufacturer:
Sanofi Genzyme Canada
Indication:
Indicated as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.
Last updated:
April 30, 2026
Blenrep (belantamab mafodotin) (in combination with bortezomib and dexamethasone)
Status:
Active negotiation
Manufacturer:
GlaxoSmithKline Inc.
Indication:
For the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy.
Last updated:
April 30, 2026
Blenrep (belantamab mafodotin) (in combination with pomalidomide and dexamethasone)
Status:
Active negotiation
Manufacturer:
GlaxoSmithKline Inc.
Indication:
For the treatment of multiple myeloma in combination with pomalidomide and dexamethasone (Bpd) in adult patients who have received at least one prior therapy including lenalidomide.
Last updated:
April 30, 2026
Status:
Active negotiation
Manufacturer:
Xediton Pharmaceuticals Inc.
Indication:
in combination with doxorubicin as first-line treatment for advanced unresectable
Last updated:
April 29, 2026
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
In combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Last updated:
April 29, 2026
Status:
Concluded with an LOI
Manufacturer:
Daiichi Sankyo Pharma Canada
Indication:
In combination with standard cytarabineand anthracycline induction and standard cytarabine consolidationchemotherapy, and as continuation maintenance monotherapy followingconsolidation, for the treatment of adult patients with newly diagnosed acutemyeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandemduplication (FLT3-ITD) positive.
Last updated:
April 29, 2026
Status:
Active negotiation
Manufacturer:
Recordati Rare Diseases Canada Inc.
Indication:
For the treatment of adult patients with Cushing's disease who have persistent or recurrent hypercortisolism after primary pituitary surgery and/or irradiation, or for whom pituitary surgery is not an option.
Last updated:
April 28, 2026
Status:
Negotiations were not pursued
Manufacturer:
Apotex Inc.
Indication:
for the treatment of adults with recurrent unresectable or metastatic nasopharyngeal carcinoma (NPC) with disease progression on or after a platinum-containing chemotherapy
Last updated:
April 27, 2026